MetadicholÃÂ® and Red Cell Distribution Width (RDW) in CKD patientsRaghavan PR*
Nanorx Inc., New York, USA
- *Corresponding Author:
- Raghavan PR
Nanorx Inc., PO Box 131, Chappaqua, NY 10514, USA
E-mail: [email protected]
Received date: June 27, 2017; Accepted date: June 30, 2017; Published date: July 06, 2017
Citation: Raghavan PR (2017) Metadichol® and Red Cell Distribution Width (RDW) in CKD patients. J Stem Cell Res Ther 7:392. doi: 10.4172/2157-7633.1000392
Copyright: © 2017 Raghavan PR. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Red blood cells originate in the bone marrow. Red cell distribution width (RDW) show sizes of circulating erythrocytes (RBC) and has been explored in several large clinical databases to be a robust marker of adverse clinical outcomes in patients. The prognostic value of RDW is seen in other conditions with end-organ dysfunction such as renal failure or. Elevated RDW levels are of significance in diseases such as kidney diseases. The high RDW levels are an indication of increased oxidative stress and closely related to the presence and poor prognosis of the disease.
No known therapy exists that can normalize RDW levels. In this paper, we present here case studies using Metadichol®  that leads to normal RDW levels in patients with CKD and PKD.